A New Benzothiazolthiazolidine Derivative, 11726172, Is Active In Vitro, In Vivo, and against Nonreplicating Cells of Mycobacterium tuberculosis

A New Benzothiazolthiazolidine Derivative, 11726172, Is Active In Vitro, In Vivo, and against Nonreplicating Cells of Mycobacterium tuberculosis

ABSTRACT Tuberculosis (TB) still poses a global menace as one of the deadliest infectious diseases. A quarter of the human population is indeed latently infected with Mycobacterium tuberculosis. People with latent infection have a 5 to 10% lifetime risk of becoming ill with TB, representing a reserv...

Full description

Bibliographic Details
Main Authors: Elena G. Salina, Umberto Postiglione, Laurent R. Chiarelli, Deborah Recchia, Monika Záhorszká, Alexander Lepioshkin, Natalia Monakhova, Adrian Pál, Alessio Porta, Giuseppe Zanoni, Jana Korduláková, Elena Kazakova, Davide Sassera, Maria Rosalia Pasca, Vadim Makarov, Giulia Degiacomi
Format: Article
Language:English
Published: American Society for Microbiology 2022-12-01
Series:mSphere
Subjects:
Mycobacterium tuberculosis
antitubercular drug
copper
latency
nonreplicating cells
Online Access:https://journals.asm.org/doi/10.1128/msphere.00369-22

Internet

https://journals.asm.org/doi/10.1128/msphere.00369-22

Similar Items